株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

炭疽菌感染症:パイプライン製品の分析

Bacillus Anthracis Infections - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 253645
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
炭疽菌感染症:パイプライン製品の分析 Bacillus Anthracis Infections - Pipeline Review, H2 2014
出版日: 2014年11月18日 ページ情報: 英文 48 Pages
概要

炭疽菌感染症の症状には、発熱、倦怠感、出血性下痢、頭痛、咳、息切れ、胸の痛みなどがあります。

当レポートでは、世界における炭疽菌感染症治療薬の開発動向を調査しており、パイプライン製品の各開発段階における比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬評価、この部門の最新動向、主要企業のレビューなどを提供しています。

イントロダクション

  • 調査範囲

炭疽菌感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

炭疽菌感染症:企業で開発中の治療薬

炭疽菌感染症:大学/機関で研究中の治療薬

炭疽菌感染症:パイプライン製品の概況

  • 初期段階の製品

炭疽菌感染症:企業で開発中の製品

炭疽菌感染症:大学/機関で研究中の製品

炭疽菌感染症の治療薬開発に従事している企業

  • Aphios Corporation
  • Evolva SA
  • Microbiotix, Inc.
  • Cellceutix Corporation
  • ContraFect Corporation

炭疽菌感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • EV-009
  • Marinus
  • EV-035
  • PMX-225
  • PMX-0196
  • PMX-0243
  • PMX-0231
  • Epimerox
  • 抗体化合物
  • TAA/ecdCD40L
  • 炭疽菌および野兎病菌感染症のためのエノイルレダクターゼを阻害する小分子
  • 感染症のためのDNAヘリカーゼを阻害する小分子
  • Gamma AApeptides
  • CF-306

炭疽菌感染症:最近のパイプライン動向

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5696IDB

Summary

Global Markets Direct's, 'Bacillus Anthracis Infections - Pipeline Review, H2 2014', provides an overview of the Bacillus Anthracis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacillus Anthracis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacillus Anthracis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bacillus Anthracis Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bacillus Anthracis Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bacillus Anthracis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bacillus Anthracis Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bacillus Anthracis Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bacillus Anthracis Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacillus Anthracis Infections Overview
  • Therapeutics Development
    • Pipeline Products for Bacillus Anthracis Infections - Overview
    • Pipeline Products for Bacillus Anthracis Infections - Comparative Analysis
  • Bacillus Anthracis Infections - Therapeutics under Development by Companies
  • Bacillus Anthracis Infections - Therapeutics under Investigation by Universities/Institutes
  • Bacillus Anthracis Infections - Pipeline Products Glance
    • Early Stage Products
    • Unknown Stage Products
  • Bacillus Anthracis Infections - Products under Development by Companies
  • Bacillus Anthracis Infections - Products under Investigation by Universities/Institutes
  • Bacillus Anthracis Infections - Companies Involved in Therapeutics Development
    • Aphios Corporation
    • Cellceutix Corporation
    • ContraFect Corporation
    • Evolva SA
    • Microbiotix, Inc.
  • Bacillus Anthracis Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CF-306 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Epimerox - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Marinus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMX-0196 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMX-0231 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMX-0243 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMX-225 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RC-100b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAA/ecdCD40L - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bacillus Anthracis Infections - Recent Pipeline Updates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bacillus Anthracis Infections, H2 2014
  • Number of Products under Development for Bacillus Anthracis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Bacillus Anthracis Infections - Pipeline by Aphios Corporation, H2 2014
  • Bacillus Anthracis Infections - Pipeline by Cellceutix Corporation, H2 2014
  • Bacillus Anthracis Infections - Pipeline by ContraFect Corporation, H2 2014
  • Bacillus Anthracis Infections - Pipeline by Evolva SA, H2 2014
  • Bacillus Anthracis Infections - Pipeline by Microbiotix, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Bacillus Anthracis Infections Therapeutics - Recent Pipeline Updates, H2 2014

List of Figures

  • Number of Products under Development for Bacillus Anthracis Infections, H2 2014
  • Number of Products under Development for Bacillus Anthracis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top